Table 1 Clinical and pathological characteristics of KRAS G12C and non-G12C mutations from the mCohort
KRAS G12C (N = 1179) | Non-G12C (N = 2819) | P-value | |
|---|---|---|---|
Age, mean (range) | 63 (31–91) | 62 (14–90) | 0.02 |
Sex, n (%) | |||
Male | 1005 (85.2%) | 1899 (67.4%) | *** |
Female | 162 (13.7%) | 875 (31.0%) | |
NA | 12 (1.0%) | 45 (1.6%) | |
Pathology, n (%) | |||
Adenocarcinoma | 1107 (93.9%) | 2584 (91.7%) | # |
Squamous carcinoma | 23 (2.0%) | 154 (5.5%) | |
Adeno-squamous carcinoma | 9 (0.8%) | 18 (0.6%) | |
LCLC | 3 (0.3%) | 13 (0.5%) | |
others | 37 (3.1%) | 50 (1.8%) | |
Stage, n (%) | |||
I | 37 (3.1%) | 85 (3.0%) | 0.24 |
II | 38 (3.2%) | 86 (3.1%) | |
III | 125 (10.6%) | 235 (8.3%) | |
IV | 447 (37.9%) | 1082 (38.4%) | |
NA | 532 (45.1%) | 1331 (47.2%) | |